XML 15 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Net revenues $ 13,959 $ 10,425 $ 26,969 $ 19,044
Cost of products sold 4,523 3,711 8,736 5,653
Selling, general and administrative 3,164 3,527 6,006 5,222
Research and development 1,802 1,582 3,584 2,961
Acquired in-process research and development 97 853 167 853
Other operating income (68) 0 (68) 0
Total operating costs and expenses 9,518 9,673 18,425 14,689
Operating earnings 4,441 752 8,544 4,355
Interest expense, net 606 614 1,228 1,042
Net foreign exchange loss 14 29 23 34
Other expense, net 2,658 802 2,263 874
Earnings (loss) before income tax expense 1,163 (693) 5,030 2,405
Income tax expense 394 46 706 134
Net earnings (loss) 769 (739) 4,324 2,271
Net earnings (loss) attributable to noncontrolling interest 3 (1) 5 (1)
Net earnings (loss) attributable to AbbVie Inc. $ 766 $ (738) $ 4,319 $ 2,272
Per share data        
Basic earnings per share (in dollars per share) $ 0.42 $ (0.46) $ 2.42 $ 1.44
Diluted earnings per share (in dollars per share) $ 0.42 $ (0.46) $ 2.41 $ 1.43
Weighted-average basic shares outstanding (in shares) 1,769 1,647 1,769 1,564
Weighted-average diluted shares outstanding (in shares) 1,776 1,647 1,776 1,568